This website is best viewed using the horizontal display on your tablet device.
With its once-daily oral dosing, SOTYKTU
offers patients a convenient option1*
The recommended dose of SOTYKTU is 6 mg orally once daily, with or without food
Dose adjustments not required
For patients ≥65 years, with renal impairment, or with mild or moderate hepatic impairment.
Dose titration not required
Drug-drug interactions minimal
(per the clinical trials)†
SOTYKTU is not recommended in combination with other potent immunosuppressants.
- Other considerations:
- Not to be initiated in patients with any clinically important active infection until it resolves or is adequately treated
- Evaluate for TB infection prior to initiating SOTYKTU. Do not administer SOTYKTU to patients with active TB
- Prior to initiating SOTYKTU, consider
completion of all age-appropriate
immunizations according to current
immunization guidelines - Not recommended in patients with severe hepatic impairment (Child-Pugh Class C)
Please see the Product Monograph for complete dosing, administration, and drug interactions information.